Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVEEmma M. Kileel, Heather J Ribaudo, Carl J Fichtenbaum et al.|The Lancet HIV|2026Cited by 2
Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trialE Segarra Martínez, V. Estrada, Esteban Martínez et al.|The Lancet HIV|2026Cited by 1